According to The Insight Partners new research study on “Endocrine Disruption Screening Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Assay Type, Application, Source of Waste, Method, End-User and Geography,” The growth of the market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.
Strategic Insights:
| Report Coverage | (Details) |
| Market Size Value in | (US$ 126.53 million in 2021) |
| Market Size Value by | (US$ 153.30 million by 2028) |
| Growth Rate | (CAGR of 2.8% during 2021 to 2028) |
| Forecast Period | (2021-2028) |
| Base Year | (2021) |
| No. of Pages | (226) |
| No. Tables | (138) |
| No. of Charts & Figures | (89) |
| Segments covered | (Assay Type, Application, Sources of Waste, Method, and End User, and Geography) |
| Regional scope | (North America; Europe; Asia Pacific; Latin America; MEA) |
| Country scope | (US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina) |
| Report coverage | (Revenue forecast, company ranking, competitive landscape, growth factors, and trends) |
Get Sample PDF Copy of Endocrine Disruption Screening Market at: https://www.theinsightpartners.com/sample/TIPRE00025912/
Many chemicals, both natural and man-made, have the potential to imitate or interfere with the endocrine system, which regulates the body's hormones. These chemicals, known as endocrine disruptors, have been linked to developmental, reproductive, brain, immunological, and other disorders. Endocrine disruptors can be present in a variety of ordinary items, such as some plastic bottles and containers, metal food can liners, detergents, flame retardants, food, toys, cosmetics, and pesticides. Pesticides, chemicals, and environmental toxins are screened using a two-tiered method for their potential effect on the oestrogen, androgen, and thyroid hormone systems by the endocrine disruptor screening.
Growing Prevalence of Endocrine Disorders Drives Endocrine Disruption Screening Market
Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D,dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.
Impact of COVID-19 Pandemic on Endocrine Disruption Screening Market
The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction in 2020. The pandemic had a negative impact on the total sales of most companies, whereas it had a favorable impact on the endocrine disruption screening market due to the increased usage of endocrine disruption screening technologies for various hormonal disorders. The lockdown due to the COVID-19 pandemic has forced people to put off getting their hormonal health checked, thus affecting the number of tests being performed and sales of screening products. Due to the COVID-19 pandemic, dealing with hormonal and mental health has become a major medical concern across the world.
Get the Latest COVID-19 Analysis on Endocrine Disruption Screening Market at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00025912
Based on assay type, the endocrine disruption screening market is bifurcated into in-vitro and in-vivo. The in-vitro segment held a larger share of the market in 2021 and is anticipated to register a higher CAGR in the market during the forecast period. The in vitro Estrogen Receptor (ER) binding experiment assesses the capacity of the radiolabeled ligand [3H]17β-estradiol ([3H]-E2) to interact with the ER in the presence of increasing quantities of a test item (i.e., competitor). Test items that possess a high affinity for the ER compete with the radiolabeled ligand at a lower concentration as compared with those compounds with lower affinity for the ER.
The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.5% during 2021–2028.
Endocrine Disruption Screening Market: Competitive Landscape and Key Developments
Creative Bioarray; Charles River Laboratories, Inc; Eurofins Scientific; Alpha Analytical, Inc.; JRF Global; Xenometrix AG; SGS SA; Smithers; and Mérieux NutriSciences are among the leading companies operating in the endocrine disruption screening market.
Order a Copy of Endocrine Disruption Screening Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00025912/
In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.3% during 2021–2028.
Browse Related Reports and get Sample copy
Endocrine Testing Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Neuroendocrine Carcinoma Market Forecast to 2028 - Covid-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
More Research: https://daulatguru.com/author/theinsightpartners/
Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the endocrine disruption screening market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.
Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email:Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/pr/endocrine-disruption-screening-market
